Generic Drugs

Mark Cuban-Owned Company To Launch Pharmacy Benefit Management Services
Kodak CEO Says Moving Forward On Generic Drug Ingredients Venture, With or Without Federal Loan
US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case
Kodak CEO Says Moving Forward On Generic Drug Ingredients Venture, With or Without Federal Loan
US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case
Teva CEO Kare Schultz On Drugmaker's Outlook, Coronavirus Response
Teva Plummets Amid Massive Price Fixing Scheme; Other Generic Drugmakers Also Fall

Generic Drugs Recent News

Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant
Teva's Cost-Cutting Plan Nets A Mizuho Upgrade
Mallinckrodt Sees Slight Positive From Tax Reform, Up To $500 Million Benefit
Goldman Sachs: Now Is The Time To Get In On Teva's Turnaround
Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy
For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst
RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist
Analyst Eats 'Some Humble Pie,' Says Teva Needs To Deliver On Greater Visibility In Coming Months
Adamas Pharma's Gocovri Will Achieve 'Blockbuster' Status, Says Kerrisdale
Endo International Piques Investor Interest After Raising Guidance
Why Is Teva Falling? Competition
What Approval For Generic Copaxone Means For Mylan
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
Teva's New CEO Is A Positive Catalyst
Mylan's Stock Is No Longer A Buy According To Analysts At Argus
Teva Downgraded As Analyst Casts Doubt On Turnaround Story
Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated
Teva's Stock Inches Higher Amid Cost-Cutting Plan
Citron On Lannett: Price Gouging At Its Worst, Will Be First To Go Bankrupt
Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision
Report: Teva Looking To Win Early EU Approval For Its Acquisition Of Allergan's Generics Unit
AstraZeneca Falls More Than 5% Following Q4 Print
Express Scripts Calls Out Valeant, Says It's 'Holding Pharmaceutical Manufacturers Accountable For Excessive Price Hikes'